Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease

Carlos Bernardes  Sara Santos  Rafaela Loureiro  Verónica Borges
Gonçalo Ramos
Gastroenterology Department, Centro Hospitalar de Lisboa Central, Lisbon, Portugal

Keywords
Bevacizumab · Rendu-Osler-Weber disease · Hereditary hemorrhagic telangiectasia · Telangiectasias · Angiodysplasias · Gastrointestinal bleeding

Abstract
Rendu-Osler-Weber disease, also known as hereditary hemorrhagic telangiectasia, is a rare autosomal dominant disorder which is often characterized by recurrent epistaxis, mucocutaneous and gastrointestinal telangiectasias, and visceral arteriovenous malformations. Patients with gastrointestinal involvement can present with a wide spectrum of severity, which may vary from uncomplicated iron deficiency anemia to continuous and refractory bleeding. We present the case of a 62-year-old female, who was admitted with anemia following several episodes of melena, and whose endoscopic examination revealed multiple angiodysplasias in the stomach and small bowel. Despite endoscopic and medical treatment attempts with hormonal agents and octreotide, she developed persistent hemorrhage and severe anemia, requiring frequent red blood cell transfusions. Immediately after initiating bevacizumab (7.5 mg/kg, every 3 weeks), complete cessation of bleeding episodes was observed. Currently, after 1 year of follow-up, she maintained sustained remission without the occurrence of adverse events.

Bevacizumab para a hemorragia gastrointestinal refractária na doença de Rendu-Osler-Weber

Palavras Chave
Bevacizumab · doença de Rendu-Osler-Weber · telangiectasia hemorrágica hereditária · telangiectasias · angiodisplasias · hemorragia gastrointestinal

Resumo
A doença de Rendu-Osler-Weber, também conhecida por telangiectasia hemorrágica hereditária, é uma doença autossômica dominante rara, frequentemente caracterizada por epistaxis recorrente, telangiectasias mucocutâneas e gastrointestinais e malformações arteriovenosas viscerais. Doentes com envolvimento gastrointestinal podem apresentar um amplo espectro de gravidade, que pode variar de anemia ferropénica não complicada até hemorragia persistente e refratária. Os autores apresentam o caso de uma mulher de 62 anos, admitida por anemia e melena recorrentes, que após o início da terapêutica endoscópica e médica com agentes hormonais e octreotide, evoluiu para hemorragia persistente e anemia grave, com necessidade de suporte transfusional frequente. Imediatamente após ter iniciado be-
sion of packed red blood cells (PRBC) (Fig. 3). Treatment with octreotide was started; however, a few hours after the first subcutaneous administration (100 µg), the patient presented with abdominal discomfort, nausea, and vomiting, leading to the discontinuation of the treatment. Given the maintenance of severe gastrointestinal bleeding, with PRBC transfusion dependence (1 unit every other day to ensure levels of 6–7 g/dL of hemoglobin), systemic therapy with bevacizumab was introduced at a dose of 7.5 mg/kg, intravenously, every 3 weeks. The patient’s clinical response was immediate: since the beginning of the therapy, she had not required any transfusion support and only had one episode of melena when an infusion was postponed for 1 week due to an upper respiratory infection (Fig. 4). After 6 weeks of treatment, the regimen was adjusted to 5 mg/kg every 3 weeks, without any change in clinical status. Currently, after 1 year of follow-up, she maintained complete clinical and biochemical remission without any adverse event.

Discussion

Gastrointestinal involvement, the second most frequent cause of bleeding in ROW patients, occurs in about one third of subjects with this condition [5]. Of those, approximately one half may develop significant disease and need regular blood transfusions [6]. The stomach and the duodenum are the most commonly affected organs [7]; notwithstanding, small bowel angiodysplasias may be found in 56–89% of the cases [8, 9]. Although endoscopic treatment with APC may be useful for patients who do not achieve control with initial general supportive measures, the use of multiple endoscopic procedures in patients with continuous blood loss is not recommended [4]. For patients like ours, presenting with refractory bleeding and consequent severe anemia, several therapeutic possibilities were described to treat vascular lesions [10]. Hormonal therapy with an estrogen-progesterone combination proved to be beneficial in a small controlled study of 9 patients, 5 of which had ROW [11]. Nonetheless, the biggest randomized controlled trial regarding this medical option failed to show a decrease in the number of bleeding episodes and transfusion requirements in noncirrhotic subjects with gastrointestinal telangiectasias [12]. Although there are no comparative studies between them, both thalidomide and octreotide long-acting release were reported to be safe and effective for patients with gastrointestinal hemorrhage [13–16]; the latter has even reduced hospital admissions and demonstrated a cost-effective benefit in this setting [15, 16]. In spite of being a generally safe drug, adverse events such as nausea, diarrhea, and flatulence are relatively common within the first hours fol-
Following administration of octreotide [14]. Although these symptoms usually resolve after the first weeks, their occurrence may represent an additional challenge. In this case, as the patient developed gastrointestinal symptoms after the first administration of octreotide, she refused further treatment with this drug and we were not able to introduce the long-acting release formulation. Therefore, given the behavior of her disease and her intolerance to octreotide, we decided to initiate bevacizumab. This recombinant humanized monoclonal antibody is directed against the vascular endothelial growth factor, a protein which plays a critical role in the pathophysiology of ROW [17]. In addition to having been successfully applied in the management of epistaxis and in the

Fig. 1. Upper digestive endoscopy revealing angiodysplasias in the gastric body (a) and second portion of the duodenum (b).

Fig. 2. Capsule endoscopy showing numerous angiodysplasias in the duodenum, jejunum, and ileum, some of which with active bleeding.

Fig. 3. Evolution of hemoglobin levels (g/dL) during hormonal therapy and despite weekly transfusion of packed red blood cells.
reduction of high cardiac output in patients with severe hepatic involvement [18], bevacizumab was shown to be effective controlling gastrointestinal bleeding in a few case reports [19–23]. In fact, patients who were refractory to several other medical and endoscopic approaches, and whose transfusion requirements ranged from 1 unit of PRBC every week to about 300 units in a year, all were reported to have developed a significant decrease in bleeding episodes and transfusion needs [19–23]. Furthermore, as in our case, authors described an extremely quick and long-term response, as well as the occurrence of early relapse following drug discontinuation [19–21]. Epperla et al. [21] published a case series comprising 5 ROW patients (4 with epistaxis and only 1 with gastrointestinal hemorrhage) who have reduced their PRBC consumption by 51–100% and their total number of emergency department visits and hospitalizations by 78%. Of note, hypertension and proteinuria were observed in 2 and 1 of those patients, respectively, during the follow-up period [21]. The optimal dose and regimen for this agent are not fully established yet. Although the majority of authors used 5 or 7.5 mg/kg every 2 or 3 weeks, successful use of low-dose bevacizumab (1 or 2 mg/kg, every 3 weeks) was already reported, which could potentially decrease drug-related costs and adverse events [22, 23]. In our patient, in whom hormonal therapy did not achieve clinical remission and who did not tolerate octreotide, intravenous bevacizumab at a dose of 5 mg/kg every 3 weeks was able to attain a dramatic and sustained response, without any complication. This case reinforces that this agent may be extremely useful for subjects who are either intolerant or refractory to alternative treatment options.

**Statement of Ethics**

This study did not require informed consent nor review/approval by the appropriate ethics committee.

**Disclosure Statement**

The authors have no conflicts of interest to declare.

**References**

Bevacizumab for Refractory Gastrointestinal Bleeding in ROW Disease

GE Port J Gastroenterol 2018;25:91–95
DOI: 10.1159/000481289